Summary
Gilead Sciences, Inc. has announced a significant development in its ongoing patent dispute with Idenix Pharmaceuticals, Inc. regarding its hepatitis C treatment, Sovaldi® (sofosbuvir). On December 1, 2014, the UK court invalidated all claims of Idenix's European Patent No. 1 523 489, which Idenix alleged was infringed by Gilead's commercialization of Sovaldi. The court's decision was based on multiple grounds, including lack of novelty, inventive step, and insufficient disclosure in Idenix's patent application. This ruling is a major win for Gilead, as it effectively dismisses Idenix's infringement claims in the UK and strengthens Gilead's position in similar ongoing legal battles in other jurisdictions. While Idenix has initiated infringement proceedings in Germany, France, and other countries, and trials are pending in Canada and Australia, the UK court's strong invalidation of the patent on several key grounds is a positive indicator for Gilead's continued market leadership in hepatitis C treatment.
Key Highlights
- 1Gilead Sciences announced the UK court invalidated all claims of Idenix Pharmaceuticals' European Patent No. 1 523 489.
- 2The UK court's decision was based on multiple grounds, including lack of novelty, inventive step, and insufficient disclosure.
- 3This ruling is favorable to Gilead's commercialization of its hepatitis C drug, Sovaldi® (sofosbuvir).
- 4Idenix had alleged that Sovaldi infringed on their patent and had initiated infringement proceedings in the UK, Germany, and France.
- 5Gilead believes Idenix's German patent is invalid for similar reasons as the UK and Norwegian patents.
- 6A corresponding Idenix patent was previously invalidated in Norway, and Gilead prevailed in a U.S. patent interference.
- 7Further trials concerning Idenix patents are scheduled in Canada (January 2015) and Australia (September 2015).